ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2847

Associations between Serum Uric Acid Level and Coronary Artery Disease

Patricia Kachur1,2, Satish Tadepalli3, Sergey Kachur4 and Pramil Cheriyath3, 1Rheumatolgy, Ochsner Foundation Hospital, New Orleans, LA, 2Internal Medicine, Ocala Regional Medical Center, Ocala, FL, 3Hackensack Meridian Health, Ocean Medical Center, Brick, NJ, 4Ocala Regional Medical Center, Ocala, FL

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Cardiovascular disease, gout, hypertension and uric acid

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: 5T099 ARHP Abstract: Clinical Aspects & Outcomes Research–ARHP II (2844–2849)

Session Type: ARHP Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Title: Association between Serum Uric Acid Level and Coronary Artery Disease

Background/Purpose: Previous studies have shown an unclear relationship between serum uric acid (SUA) and coronary artery disease (CAD). We attempt to clarify this relationship using the largest public US dataset available; the National Health and Nutrition Examination Survey (NHANES).

Methods: NHANES data from 2003 to 2014 was selected based on an affirmative response to the questions: 1. “Ever told you had angina/angina pectoris”, 2. “Ever told you had heart attack”, and 3. “Ever told you had coronary heart disease”. The resulting data set was analyzed for uric acid levels (cut-off >6.0 mg/dL in females and >7.0 mg/dL in males), and CAD risk factors. Proportional analyses as well as univariate and multiple logistic regression models were used to evaluate the associations between SUA levels and CAD.

Results: 36,267 survey participants (Mean age 49.35 yrs.) from 2003 to 2014 were included in the study. There were 20,201(51.7%) females and 18863 (48.3%) males. A total of 2797 (7.2%) had CAD; 39% of these were female and 61% were male. Univariate analyses showed a significant association between high SUA levels (OR 1.4; 95% CI 1.3 – 1.6), hypertension (OR 1.1; 95% CI 1 – 1.2), and renal dysfunction (OR 2.0; 95% CI 1.8 – 2.3). The relationship between SUA and CAD was reaffirmed in our multiple regression models (p-value <0.001) after adjusting for age, sex, race, smoking, diabetes, blood pressure and cholesterol.

Conclusion: Our study showed that there is a significant association between SUA levels and CAD in the NHANES population. This suggests that including SUA in risk models may improve risk stratification for CAD. Further prospective studies are needed to confirm this association and clarify the mechanisms behind it.


Disclosure: P. Kachur, None; S. Tadepalli, None; S. Kachur, None; P. Cheriyath, None.

To cite this abstract in AMA style:

Kachur P, Tadepalli S, Kachur S, Cheriyath P. Associations between Serum Uric Acid Level and Coronary Artery Disease [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/associations-between-serum-uric-acid-level-and-coronary-artery-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/associations-between-serum-uric-acid-level-and-coronary-artery-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology